Daniela Späth

6.0k total citations · 2 hit papers
26 papers, 3.1k citations indexed

About

Daniela Späth is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Daniela Späth has authored 26 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Hematology, 12 papers in Molecular Biology and 10 papers in Genetics. Recurrent topics in Daniela Späth's work include Acute Myeloid Leukemia Research (23 papers), Chronic Myeloid Leukemia Treatments (9 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (9 papers). Daniela Späth is often cited by papers focused on Acute Myeloid Leukemia Research (23 papers), Chronic Myeloid Leukemia Treatments (9 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (9 papers). Daniela Späth collaborates with scholars based in Germany, Austria and United States. Daniela Späth's co-authors include Richard F. Schlenk, Konstanze Döhner, Hartmut Döhner, Lars Bullinger, Arnold Ganser, Marianne Habdank, Jürgen Krauter, Brigitte Schlegelberger, Andrea Corbacioglu and Katharina S. Götze and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Daniela Späth

26 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia

2008 1.1k citations Richard F. Schlenk, Konstanze Döhner et al. New England Journal of Medicine profile →
IDH1andIDH2Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia WithNPM1Mutation WithoutFLT3Internal Tandem Duplication

2010 578 citations Peter Paschka, Richard F. Schlenk et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniela Späth Germany	12	2.6k	1.5k	1.0k	680	594	26	3.1k
Frédérik Damm Germany	23	1.7k 0.6×	1.2k 0.8×	780 0.8×	306 0.5×	492 0.8×	58	2.2k
Toshiki Iwai Japan	14	1.3k 0.5×	777 0.5×	519 0.5×	273 0.4×	149 0.3×	36	1.9k
Pascual Bolufer Spain	23	1.2k 0.5×	1.4k 0.9×	245 0.2×	503 0.7×	184 0.3×	65	2.0k
Angelo Guerrasio Italy	24	938 0.4×	787 0.5×	547 0.5×	315 0.5×	128 0.2×	105	1.7k
Erica Travaglino Italy	20	2.0k 0.8×	488 0.3×	1.3k 1.3×	198 0.3×	107 0.2×	57	2.3k
Yana Pikman United States	15	1.8k 0.7×	1.5k 1.0×	2.0k 2.0×	155 0.2×	93 0.2×	41	2.7k
Henrik Lilljebjörn Sweden	22	673 0.3×	588 0.4×	226 0.2×	610 0.9×	264 0.4×	51	1.6k
Salil Goorha United States	9	789 0.3×	573 0.4×	194 0.2×	826 1.2×	184 0.3×	15	1.6k
Rachel Okabe United States	15	1.0k 0.4×	1.2k 0.8×	1.0k 1.0×	68 0.1×	125 0.2×	22	2.0k
Mikael Behrendtz Sweden	22	639 0.2×	679 0.4×	136 0.1×	837 1.2×	183 0.3×	40	1.6k

Countries citing papers authored by Daniela Späth

Since Specialization

Citations

This map shows the geographic impact of Daniela Späth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniela Späth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniela Späth more than expected).

Fields of papers citing papers by Daniela Späth

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniela Späth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniela Späth. The network helps show where Daniela Späth may publish in the future.

Co-authorship network of co-authors of Daniela Späth

This figure shows the co-authorship network connecting the top 25 collaborators of Daniela Späth. A scholar is included among the top collaborators of Daniela Späth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniela Späth. Daniela Späth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Krönke, Jan, Lars Bullinger, Veronica Teleanu, et al.. (2013). Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. Blood. 122(1). 100–108. 181 indexed citations

Nagel, Gabriele, Tanja Stocks, Daniela Späth, et al.. (2012). Metabolic factors and blood cancers among 578,000 adults in the metabolic syndrome and cancer project (Me-Can). Annals of Hematology. 91(10). 1519–1531. 40 indexed citations

Fiedler, Walter, Sabine Käyser, Maxim Kebenko, et al.. (2012). Sunitinib and Intensive Chemotherapy in Patients with Acute Myeloid Leukemia and Activating FLT3 Mutations: Results of the AMLSG 10-07 Study (ClinicalTrials.gov No. NCT00783653). Blood. 120(21). 1483–1483. 10 indexed citations

Gaidzik, Verena I., Peter Paschka, Daniela Späth, et al.. (2012). TET2 Mutations in Acute Myeloid Leukemia (AML): Results From a Comprehensive Genetic and Clinical Analysis of the AML Study Group. Journal of Clinical Oncology. 30(12). 1350–1357. 141 indexed citations

Gaidzik, Verena I., Richard F. Schlenk, Peter Paschka, et al.. (2011). DNMT3A mutations Predict for Inferior Outcome in NPM1-Wildtype and Molecular Unfavorable Cytogenetically-Normal Acute Myeloid Leukemia: A Study of the German-Austrian AMLSG. Blood. 118(21). 415–415. 2 indexed citations

Gaidzik, Verena I., Lars Bullinger, Richard F. Schlenk, et al.. (2011). RUNX1Mutations in Acute Myeloid Leukemia: Results From a Comprehensive Genetic and Clinical Analysis From the AML Study Group. Journal of Clinical Oncology. 29(10). 1364–1372. 328 indexed citations

Paschka, Peter, Richard F. Schlenk, Julia Herzig, et al.. (2011). ASXL1 Mutations Predict for Resistance to Chemotherapy and Inferior Outcome in Younger Adult Patients with Acute Myeloid Leukemia (AML): A Study of the German-Austrian AMLSG. Blood. 118(21). 412–412. 3 indexed citations

Paschka, Peter, Richard F. Schlenk, Verena I. Gaidzik, et al.. (2010). IDH1andIDH2Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia WithNPM1Mutation WithoutFLT3Internal Tandem Duplication. Journal of Clinical Oncology. 28(22). 3636–3643. 578 indexed citations breakdown →

Rücker, Frank G., Stephan Stilgenbauer, Martin Bommer, et al.. (2010). Induction Therapy with Idarubicin and Etoposide Combined with Sequential or Concurrent Azacitidine In Patients with High-Risk Acute Myeloid Leukemia: Pilot-Phase of the AMLSG 12-09 Study. Blood. 116(21). 2184–2184. 1 indexed citations

10.

Tassara, Michela, Konstanze Döhner, Marie von Lilienfeld‐Toal, et al.. (2010). Prospective Phase III Trial of Valproic acid (VPA) In Combination with All-Trans Retinoic Acid (ATRA) and Intensive Induction Therapy for AML In Older Patients: The German-Austrian AMLSG 06-04 Study. Blood. 116(21). 185–185. 1 indexed citations

11.

Krönke, Jan, Richard F. Schlenk, Karina Eiwen, et al.. (2009). Identification of Clinically Relevant Predictive MRD Checkpoints in AML Patients with NPM1 Mutations: A Study of the AML Study Group (AMLSG).. Blood. 114(22). 1586–1586. 2 indexed citations

12.

Käyser, Sabine, Richard F. Schlenk, Frank Breitenbuecher, et al.. (2009). Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. Blood. 114(12). 2386–2392. 198 indexed citations

13.

Paschka, Peter, Juan Du, Richard F. Schlenk, et al.. (2009). Mutations in the Fms-Related Tyrosine Kinase 3 (FLT3) Gene Independently Predict Poor Outcome in Acute Myeloid Leukemia (AML) with t(8;21): A Study of the German-Austrian AML Study Group (AMLSG).. Blood. 114(22). 825–825. 3 indexed citations

14.

Voso, Maria Teresa, Stefan Hohaus, Francesco Guidi, et al.. (2008). Prognostic role of glutathione S-transferase polymorphisms in acute myeloid leukemia. Leukemia. 22(9). 1685–1691. 32 indexed citations

15.

Schlenk, Richard F., Konstanze Döhner, Jürgen Krauter, et al.. (2008). Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia. New England Journal of Medicine. 358(18). 1909–1918. 1103 indexed citations breakdown →

16.

Schlenk, Richard F., Konstanze Döhner, Michael Kneba, et al.. (2008). Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B. Haematologica. 94(1). 54–60. 144 indexed citations

17.

Krönke, Jan, Richard F. Schlenk, Karina Eiwen, et al.. (2008). Monitoring of Minimal Residual Disease in NPM1 Mutated Acute Myeloid Leukemia (AML): Results of the AML Study Group (AMLSG). Blood. 112(11). 699–699. 1 indexed citations

18.

Schlenk, Richard F., Andrea Corbacioglu, Jürgen Krauter, et al.. (2006). Gene Mutations as Predicitive Markers for Postremission Therapy in Younger Adults with Normal Karyotype AML.. Blood. 108(11). 4–4. 14 indexed citations

19.

Schlenk, Richard F., Jürgen Krauter, Stefan Fröhling, et al.. (2005). Postremission Therapy with an Allogeneic Transplantation from an HLA-Matched Family Donor Seems To Overcome the Negative Prognostic Impact of FLT3-ITD in Younger Patients with Acute Myeloid Leukemia Exhibiting a Normal Karyotype.. Blood. 106(11). 2353–2353. 1 indexed citations

20.

Späth, Daniela. (2000). Treatment of chronic fatigue syndrome with 5-HT3 receptor antagonists - preliminary results. Scandinavian Journal of Rheumatology. 29(sup113). 72–77. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact